
William J. Catalona, MD, explains how prostate-specific antigen (PSA) testing revolutionized screening and treatment of prostate cancer.

William J. Catalona, MD, explains how prostate-specific antigen (PSA) testing revolutionized screening and treatment of prostate cancer.

"As we celebrate the tremendous victories against cancer and commemorate 5 decades of progress, we are also reminded of the harsh reality that we have a war still to be won," writes Michael S. Cookson, MD, MMHC, co–editor in chief of Urology Times.

Check for surgical approach and bundling edits when choosing a code.

Be sure to check and refresh your practice’s policies for record requests.

Lawsuit was resolved at mediation for $3,500,000.

Loan repayment assistance programs and refinancing are options.

"Our hospital doesn’t have a [COVID-19 vaccination] mandate. A mandate would cost us a handful of nurses," says 1 urologist.

“Yoga improved quality of life in men compared to the standard of care, specifically on the fatigue scale, meaning they were less tired; on sexual function; and on their functional, physical and social wellbeing,” said Dharam Kaushik, MD.

“The initial phase 1b data of batiraxcept in combination with cabozantinib are impressive and point toward the role of dual AXL and VEGF inhibition in the treatment of clear cell renal cell carcinoma,” said Eric Jonasch, MD.

"At the end of the day, the idea is that it shows you what your next steps are based on what the AUA and SUO guidelines are for non–muscle invasive bladder cancer," says Chad R. Ritch, MD, MBA, FACS.

"These findings underscore the importance of screening guidelines from the task force and the rapid responsiveness of clinicians and patients,” said Michael S. Leapman, MD.

In this interview, Michael Schweizer, MD, highlights a study of olaparib plus bipolar androgen therapy in patients with metastatic castration-resistant prostate cancer.

International Index of Erectile Function-Erectile Function (IIEF-EF) score increased in patients receiving nutraceuticals.

Neoadjuvant chemotherapy significantly benefited patients with classifier-identified non-luminal tumors.

"For patients who can maintain a functional implant in-situ, long-term patient satisfaction rates remain high," said Elodie Beels, MD.